Glen Clack, Sercan Aksoy, Meritxell Bellet-Ezquerra, Begoña Bermejo de las Heras, Arslan Cagatay, Maria Castro-Henriques Pinto-Machado, Irfan Cicin, Mahmut Gumus, Carmen Hinojo-González, Nuri Karadurmus, Denisse Lee Cervantes, Rebeca Lozano Mejorada, Emmanuel de la Mora Jimenez, Fernando Moreno Anton, Sonia Pernas, Timothy J. Pluard, Carlos Zuloaga Fernandez del Valle, Ozan Yazıcı, Stuart McIntosh
SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor samuraciclib in advanced hormone receptor-positive breast cancer after CDK4/6 inhibitor
Dec. 05, 2023
SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor samuraciclib and selective estrogen receptor degrader elacestrant in advanced hormone receptor positive breast cancer after CDK4/6 inhibitor
Dec. 05, 2023
Amita Patnaik, Silvia Antolín Novoa, Meritxell Bellet-Ezquerra, François-Clément Bidard, Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo, Sacha J. Howell, Rinath M. Jeselsohn, Simon Lord, Paolo Mazzei, Maria de Miguel Luken, Erin Roesch, Agostina Stradella, Helene Vanacker, Cecile Vicier, Seth A. Wander, Glen Clack, Stuart McIntosh
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Jul. 24, 2023
R. Charles Coombes , Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh & Matthew G. Krebs
Identification of an orally bioavailable dual Cyclin-K glue degrader – CDK12/13 inhibitor’
Dec. 01, 2021
Edward K. Ainscow, Adrian Campbell, Michael Cripps, Robert Workman, Stuart Thomson, Kam Chohan, Samien Crepin, Mahiro Sunose, Jamie Patient, Jane Kendrew, Ash Bahl
Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype
Jun. 01, 2020
Edward K. Ainscow
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Dec. 09, 2021
M.G. Krebs, S. Lord, L. Kenny, R.D. Baird, I. MacPherson, A. Bahl, G. Clack, E. Ainscow, A.G. Barrett, P. Dickinson, M.J. Fuchter, M. Lehnert, S. Ali, S. Mcintosh, R.S. Coombes
A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
Dec. 08, 2021
Sacha J Howell, Laura M Kenny, Simon Lord, Matthew G Krebs, Tobias Arkenau, Richard Baird, Iain R MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Athony GM Barrett, Paul A Dickinson, Matthew J Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh, Charles Coombes
Study of samuraciclib(CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Sep. 01, 2021
S.J. Howell, M.G. Krebs, S. Lord, L. Kenny, A. Bahl, G. Clack, E. Ainscow, H.I. Arkenau, J.L. Mansi, C. Palmieri, P. Richards, R. Jeselsohn, Z. Mitri, W.J. Gradishar, S. Sardesai, J. O'Shaughnessy, M. Lehnert, S. Ali, S. McIntosh, R.C. Coombes
The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Jun. 29, 2022
Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan
2.5 Angstrom – resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942
Feb. 16, 2021
Basil J. Gerber, Johnathan Remis, Simak Ali, Eva Nogales